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Abstract
Background: Diffuse intrinsic pontine glioma (DIPG) is an aggressive pediatric brainstem tumor. Most DIPGs harbor
a histone H3 mutation, which alters histone post-translational modification (PTM) states and transcription. Here, we
employed quantitative proteomic analysis to elucidate the impact of the H3.3K27M mutation, as well as radiation
and bromodomain inhibition (BRDi) with JQ1, on DIPG PTM profiles.
Methods: We performed targeted mass spectrometry on H3.3K27M mutant and wild-type tissues (n = 12) and cell
lines (n = 7).
Results: We found 29.2 and 26.4% of total H3.3K27 peptides were H3.3K27M in mutant DIPG tumor cell lines and
tissue specimens, respectively. Significant differences in modification states were observed in H3.3K27M specimens,
including at H3K27, H3K36, and H4K16. In addition, H3.3K27me1 and H4K16ac were the most significantly distinct
modifications in H3.3K27M mutant tumors, relative to wild-type. Further, H3.3K36me2 was the most abundant co-
occurring modification on the H3.3K27M mutant peptide in DIPG tissue, while H4K16ac was the most acetylated
residue. Radiation treatment caused changes in PTM abundance in vitro, including increased H3K9me3. JQ1
treatment resulted in increased mono- and di-methylation of H3.1K27, H3.3K27, H3.3K36 and H4K20 in vitro.
Conclusion: Taken together, our findings provide insight into the effects of the H3K27M mutation on histone
modification states and response to treatment, and suggest that H3K36me2 and H4K16ac may represent unique
tumor epigenetic signatures for targeted DIPG therapy.
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Background
Pediatric high-grade glioma is the leading cause of cancer
death in children [1]. Diffuse intrinsic pontine glioma
(DIPG) is a high-grade glioma that arises in the brainstem,
with an overall survival of only 11months [2]. DIPG can-
not be removed surgically, and there is no known effective
treatment. Standard management is with radiotherapy,
which temporarily relieves symptoms but only confers a
survival benefit of three months [3]. Since DIPGs ultim-
ately exhibit treatment resistance and disease progression,
better understanding of tumor biology is desperately
needed to identify effective therapeutic therapy [4].
Recent studies suggest that changes in epigenetic regu-
lation of gene transcription play a key role in pediatric
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gliomagenesis and response to treatment [5–7]. Dynamic
post-translational modifications (PTMs) on the histone
N-terminal tail, rendered by histone modifying enzymes,
alter chromatin structure to facilitate open reading (eu-
chromatin) or silencing (heterochromatin) throughout
the genome [5, 8–10]. Specific patterns of histone PTMs
represent an epigenetic signature, or histone code,
reflecting a relative transcriptional state. In up to 80% of
DIPGs, heterozygous somatic mutations in genes encod-
ing histone H3 isoforms H3.1 and H3.3 (HIST1H3B and
H3F3A, respectively) substitute methionine for lysine at
amino acid residue 27 on the H3 N-terminal tail
(H3K27M) [11]. This H3K27M mutant protein alters
histone H3 PTMs in DIPG, impacting chromatin struc-
ture and hence gene expression [5, 7, 12].
For example, histone H3K27 di- and tri-methylation
(H3K27me2/3), transcriptionally silencing marks, are re-
duced in H3K27M DIPG, de-repressing transcription
[13–15]. H3K27me2/3 loss is accompanied by increased
H3K27ac and the formation of heterotypic H3K27M/
H3K27ac nucleosomes that colocalize with bromodo-
main proteins 2 and 4 (BRD2/4) and RNA polymerase
II, suggesting a potential role of BRD proteins in DIPG
pathogenesis [7, 16]. We demonstrated pre-clinical effi-
cacy of bromodomain inhibition (BRDi) with JQ1, a bro-
modomain and extra terminal domain (BET) inhibitor,
resulting in reduction of H3K27ac and restoration of
H3K27me3 [7]. These findings suggest that changes in
epigenetic regulation of gene expression in DIPG may be
reflected by histone codes, and detection of these signa-
tures could shed light on mechanisms of tumorigenesis.
Here, we employ targeted mass spectrometry via mul-
tiple reaction monitoring (MRM) to characterize 93 dis-
tinct PTM states in H3.3K27M mutant DIPG specimens,
and investigate the effects of radiation and bromodo-
main inhibition on tumor epigenetic signatures.
Materials and methods
Tissue specimens
Pediatric DIPG tumor tissue (n = 9, H3.3K27M mutant)
was collected postmortem (IRB #Pro00001339).
H3.3K27 wild-type (WT) adult glioma tumor tissue
specimens (n = 2), and one non-tumor frontal lobe tissue
specimen were collected during the course of treatment
(IRB# STU00095863). All diagnoses were made radio-
graphically by a neuroradiologist, then confirmed by
neuropathological evaluation upon tissue collection. Pa-
tient identifiers were removed and a single sequential
numerical identifier assigned to each specimen (Table 1).
Tissues were stored at − 80 °C prior to proteomic ana-
lysis (IRB #STU00202063).
Cell lines
Patient-derived pediatric DIPG cell lines SF8628, SF7761,
DIPG007 (H3.3K27M mutant) and high-grade glioma
cells KNS42 (H3.3G34V mutant) and SF9427 (H3.3G34
Table 1 Summary of specimens analyzed with histone tail mass spectrometry
ID Specimen type Histone Status Gender Age (Years)
1 DIPG tissue H3.3K27M F 5
2 DIPG tissue H3.3K27M M 8
3 DIPG tissue H3.3K27M M 7
4 DIPG tissue H3.3K27M M 19.6
5 DIPG tissue H3.3K27M F 7
6 DIPG tissue H3.3K27M M 7.6
7 DIPG tissue H3.3K27M M 6
8 DIPG tissue H3.3K27M M 6
9 DIPG tissue H3.3K27M M 6.25
10 GBM tissue H3.3G34R N/A 45
11 GBM tissue Wild type N/A 50
12 Focal cortical dysplasia, frontal lobe Wild type N/A 62
SF7761 DIPG cell line H3.3K27M N/A N/A
SF8628 DIPG cell line H3.3K27M N/A N/A
DIPG 007 DIPG cell line H3.3K27M N/A N/A
KNS 42 GBM cell line H3.3G34V N/A N/A
SF9427 Pediatric GBM cell line Wild type N/A N/A
U87 Adult GBM cell line Wild type N/A N/A
NHA Normal human astrocytes Wild type N/A N/A
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wild-type) were provided by Dr. Rintaro Hashizume
(Northwestern University) as previously described
[17–19]. H3 wild-type adult glioma cells (U87) and
normal human astrocytes (NHA) were obtained from
American Type Culture Collection and ScienCell
(#1800), respectively. Cells were treated with 300 nM
JQ1 (Selleckchem S7110) or DMSO (Sigma D2650) for
24 and 48 h. Cell irradiation (9 Gy) was performed
with the RadSOURCE-2000 X-Ray Irradiator, and cells
analyzed at 24 and 48 h. Cell pellets were generated by
harvesting with trypsin and washing twice with PBS,
then stored at − 80 °C prior to proteomic analysis.
Western blotting
Histones were extracted from cell pellets using Histone
Extraction Kit (ab113476, Abcam) according to the man-
ufacturer’s protocol. 0.5 μg Histones were loaded and
separated by SDS-PAGE using a 12% Mini-PROTEAN®
TGX™ Precast Protein Gels and transferred by using
Trans-Blot Turbo Mini 0.2 μm PVDF Transfer Packs at
2.5A, 25 V for 3 min in a Trans-Blot Turbo™ Transfer
Systems (Bio-Rad). The membrane was blocked prior to
the addition of the primary antibody with 5% milk in
Tris buffered saline with 0.1% of Tween 20. The mem-
brane was incubated overnight with primary antibody in
TBS buffer with 0.1% Tween and 5% milk. The dilution
of primary antibody was as follows: Rabbit monoclonal
anti-Histone H3 (mutated K27M) antibody (ab190631)
at a dilution of 1:1000, Rabbit mAb Acetyl-Histone H3
(Lys27) (D5E4) XP ((#8173, Cell Signaling Technology)
at a dilution of 1:1000, Mouse mAb Histone H3 (1B1B2)
(#14269, Cell Signaling Technology) at a dilution of 1:
1000. The membrane was washed 3 times with TBS/
0.1% Tween and incubated with an anti-rabbit or anti-
mouse IgG conjugated to horse radish peroxidase (7074
and 7076, Cell Signaling Technology) at a 1:2000 dilu-
tion in TBS/0.1% Tween and 5% milk. Pierce ECL Plus
Western Blotting Substrate (CN: 32132, Thermo Scien-
tific) was used according to the manufacturer’s protocol
to visualize proteins and quantify band intensity. Experi-
ments were performed in triplicate for statistical ana-
lysis. The intensity of protein bands were analyzed by
ImageJ, with the relative protein value expressed via the
ratio of specific protein/H3.
Gene expression profiling
Total cell RNA was extracted for gene expression profil-
ing based on manufacturer protocol (Qiagen). All sam-
ples were adjusted to a concentration of 20 ng/μl RNA
prior to submission for gene expression analysis using
the NanoString nCounter Plexset Analysis System DNA
damage repair 96 gene codeset (NanoString Technolo-
gies, Seattle, WA). Gene expression values were deter-
mined and converted to fold change in expression level
for each treatment condition compared to DMSO controls
in order to determine statistically significant differences in
gene expression levels between groups (NanoString).
Functional pathways and gene ontology analysis was then
performed on fold change expression values (Inginuity
Pathways Analysis, Qiagen).
Histone preparation for targeted mass spectrometry
Nuclei were isolated in buffer (15 mM Tris-HCl pH 7.5,
60 mM KCl, 15 mM NaCl, 5 mM MgCl2, 1 mM CaCl2,
250 mM sucrose; 1 mM DTT, 1:100 HALT protease in-
hibitor (Thermo Scientific)), and 10 mM sodium butyr-
ate added immediately prior to use containing 0.3% NP-
40. Nuclei were centrifuged at 600 x g for five minutes
at 4 °C and washed twice with nuclear isolation buffer.
Histones were extracted by via five volumes of H2SO4
and incubated at room temperature one hour. Debris
was removed by centrifugation at 4000 x g for five mi-
nutes. Trichloroacetic acid was added to the supernatant
at a final concentration of 20% (v/v) and incubated over-
night at 4 °C. Precipitated histones were pelleted at 10,
000 x g for five minutes, washed once with ice-cold acet-
one with 0.1% HCl and twice with acetone at 15,000 x g
for five minutes. Residual acetone was dried in a fume
hood, and samples stored at − 20 °C until further pro-
cessing. Histones were derivatized with a single round of
propionylation, digested with 1 μg trypsin (Promega,
Madison, WI), and derivatized again with a single round
of propionylation according to Garcia et al. [20].
Targeted LC-MS/MS of histone peptides
Histone peptides were resuspended in Loading Buffer
(0.1% TFA in water) and analyzed on a Thermo TSQ
Quantiva (Thermo Scientific) in-line with a Dionex
nano-LC (Sunnyvale, CA). Peptides were loaded onto a
trapping column (3 cm × 150 μm, packed with ProntoSIL
C18-AQ, 3 μm, 200 Å resin (New Objective, Woburn,
MA)) for 10 min at 2.5 μL/min with 100% Loading Buf-
fer. Elution from the trapping column and separation on
a PicoChip analytical capillary column (10 cm × 75 μm
packed with ProntoSIL C18-AQ, 3 μm, 200 Å resin (New
Objective)) was achieved by decreasing the percentage of
Solvent A (0.1% formic acid in water) and increasing the
percentage of Solvent B (0.1% formic acid in 95% aceto-
nitrile) from 1 to 35% at a flow rate of 0.30 μL/min over
45 min. The peptides were introduced into the triple
quadrupole mass spectrometer by electrospray from an
emitter with a 10 μm tip. The instrument settings were
as follows: collision gas pressure of 1.5 mTorr; Q1 peak
width of 0.7 (FWHM); cycle time of 3 s; skimmer offset
of 10 V; electrospray voltage of 2.5 kV. All injections
were performed in technical triplicate. Targeted methods
were performed as previously published [21]. A list of
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monitored peptide transitions is provided (Supplemen-
tary material 1).
Quantitation of histone modification states
Raw data were imported into Skyline with Savitzky-
Golay smoothing for analysis. Peak area assignments
were manually confirmed, and total peak areas used to
determine the percent relative abundance of histone
modifications. The percent relative peptide abundance
was determined by dividing the area under the curve for
a given peptide of interest by the sum of the areas under
the curve for all peptides with the same sequence, then
multiplying by 100. Heatmaps were generated with R
using gplots package, and show modifications that were
above the limit of detection in all samples.
Statistical analysis
Differences in peptide abundance were analyzed using
independent-sample t test for between-group compari-
sons, or one-way ANOVA and Tukey’s post hoc test for
multi-group analyses using SPSS (IBM, Version 25), and
expressed as mean ± standard deviation (SD). Pearson
Correlation was performed to analyze the relationship
between H3.3K27M mutation and detected histone
codes. Multivariable analysis was performed using linear
regression with Stepwise entry (p = 0.05) and removal
(p = 0.10). All p values were two-sided, with p < 0.05
considered statistically significant.
Results
Glioma cell histone codes are distinct by H3.3K27M
mutation status
Using MRM, we determined histone N-terminal tail sig-
natures (histone codes) in H3.3K27M mutant and wild
type (WT) glioma cell lines and astrocytes (Supplemen-
tary material 2, Table 1). Histone codes were distinct by
H3 mutation status (Fig. 1a). K27 di- and tri-methylation
(K27me2/3) were significantly decreased in H3.3K27M
mutant cells on H3.1 and H.3.3 isoforms (Fig. 1a, Sup-
plementary material 3, 4). A significant difference in
H3.1K27me3 was also observed, with a mean relative
abundance of 15.9% versus 1.4% in mutant versus WT
lines (Fig. 1b). A similar trend was observed on H3.3,
with H3.3K27me3 relative abundance of 5.6% in
H3.3K27 WT cells and only 0.6% in mutants (Fig. 1c).
We observed greater K36 di- and tri-methylation in mu-
tants, coupled with less abundant H3.1K36me (Fig. 1d,
e). H3K79me2 was less abundant in H3.3K27M mutant
cells compared to WT (mean = 8.3 and 16.3%, respect-
ively, Fig. 1f).
Histone acetylation also differed based on mutation
status. Acetylation at H4K16 was lower in H3.3K27 WT
cells compared to mutant (31.5 and 48.2%, respectively
Fig. 1g). H3.1K27me2 and H3.1K36me2 were the most
common PTMs associated with H3.3K27M mutant peptide
on multivariate analysis (F = 428.7, p < 0.01). Importantly,
because the H3F3A mutation yielding the H3.3K27M mu-
tant protein is heterozygous, we quantified relative abun-
dance of H3.3K27 WT and H3.3K27M peptides in a given
cell sample: 29.2% of H3.3K27 peptides in our mutant cell
lines were H3.3K27M (SD= 6.6, range 22.2–35.4%, n = 3.
Figure 1c). As expected, the H3.3K27M peptide was not
detected in H3.3K27 WT cells.
Glioma tissue histone codes are distinct by H3.3K27M
mutation status
Tissue histone PTM profiles also clustered by H3.3K27M
mutation status (Fig. 2a). The relative abundance of 16
PTMs were statistically significantly different between
H3.3K27M mutant and WT tissues (Supplementary mater-
ial 5). As with cell lines, the greatest differences in PTMs
between H3.3K27M mutant and WT tissues were K27 and
K36 methylation states (Fig. 2b-e, Supplementary material
5). We also detected significantly greater acetylation of
H2AK5, H4K5, H4K8, H4K12, and H4K16 (Fig. 2f).
H3.3K27me1 and H4K16ac were the most common PTM
states associated with H3.3K27M peptide abundance on
multivariate analysis (F = 214.0, p < 0.01).
As the greatest difference in relative abundance of
PTM states in H3.3K27M mutant specimens were ob-
served at H3K27, H3K36 and multiple H4 tail amino
acids, we queried for the predominant modification
states at these residues to determine correlations be-
tween specific modification states at these locations
(Fig. 3). Overall, K27me1 and K36me2 were the predom-
inant modifications observed on H3.1 and H3.3 isoforms
(Fig. 3a), while acetylation was greatest at H4K16 (Fig.
3b). H3.3K36me2 abundance positively correlated with
H3.1K36me2 levels, and negatively correlated with
H3.3K27me1 (Fig. 3c, d). Also, H4K16ac abundance cor-
related positively with H3.3K36me2, and negatively with
H3.3K27me1 (Fig. 3e, f).
We also quantified the relative abundance of H3.3K27
WT and H3.3K27M peptides in a given tissue sample.
Similar to cell lines, 26.44% of H3.3K27 peptides in our
mutant tumor specimens were H3.3K27M (SD = 10.7,
range 5.2–44.5%, n = 9), with no mutant peptides de-
tected in WT tissues.
Lastly, we compared DIPG cell and tumor tissue epi-
proteomic profiles. Overall, modifications on the H3.1/
H3.3K27 N-terminal tail were similar in DIPG cell lines
and tumor tissues. Specifically, there was no significant
difference in abundance of the majority of H3.1/
H3.3K27 peptides quantified, with differential fold
change (FC) in abundance > 2 or < 0.5 for only six pep-
tide modification states between DIPG cells and tissues
(Table 2, Supplementary material 6). Significant differ-
ences in peptide modification states between groups
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were observed on H1.4K25, H3.3K36, H3K79, H3K9,
and H4K20 peptides. Importantly, no difference in rela-
tive H3.3K27M peptide abundance was detected be-
tween DIPG tissue and cell lines (mean = 26.4 and 29.2,
respectively, p = 0.686). Of note, unmodified peptides
and modifications with < 5% relative abundance were ex-
cluded from this comparative analysis to ensure bio-
logical significance.
Co-occurring histone modification states in tissue
specimens
Because our method requires protein digestion for sub-
sequent peptide mass spectrometry, determination of
co-occurring PTMs at distant amino acid residues along
the N-terminal tail is not possible. However, PTMs at
proximal amino acids on the same peptide can be
assessed. Therefore, to further explore the relationship
Fig. 1 Histone peptide modification states in pediatric glioma cell lines. a Unsupervised hierarchical clustering of pediatric glioma cell line histone
tail modification profiles reveals clustering by H3K27M mutation status. b-e Bar graph showing that relative abundance of modifications at
H3.1K27/K36 and H3.3K27/K36 in glioma cell lines are distinct by H3.3K27M mutation status. f-g Statistically significant differences in H3K79me2
and H4K16ac abundance are observed in H3.3K27M mutant glioma cell lines (n = 3) compared to H3.3K27 WT (n = 4). * p < 0.05 compared to
H3.3K27 WT group, independent-sample t test, two-tailed. un = unmodified, me1 =mono-methylation, me2 = di-methylation,
me3 = tri-methylation, ac = acetylation
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between the H3.3K27M mutant peptide and histone PTM
states, we investigated the PTMs of H3K27/K36 and
H4K5/K8/K12/K16 peptides. The relative abundance of
ten combinations of PTM states along these peptides were
significantly different by tissue H3.3K27M mutation status
(Fig. 4a, Supplementary material 7). Of these,
H3.1K27me1K36me2, H3.3K27MK36me2, and H4K5un-
K8acK12unK16ac were increased in mutants compared to
WT. These findings are consistent with the single amino
acid analysis presented above. Further, we observed a
positive correlation between H3.1K27me1K36me2 and
H3.3K27M peptide abundance, and a negative correlation
between H3.1K27me1K36me3 and H3.3K27M peptide
abundance (Fig. 4b, c, Supplementary material 7). The
abundance of the H4K5unK8acK12unK16ac peptide
also positively correlated with H3.3K27M peptide
Fig. 2 Tissue histone peptide modification states differ by H3.3K27M mutation status. a Unsupervised hierarchical clustering of glioma and normal
brain tissue histone tail modification profiles reveals clustering by H3.3K27M mutation status. b-e Bar graph showing relative modifications at
H3.1K27/K36 and H3.3K27/K36 in tissue specimens are distinct by H3.3K27M mutation status. f Statistically significant modifications of H2 and H4
acetylation are observed in H3.3K27M mutant tissues (n = 9) compared to H3.3K27 WT (n = 3).* p < 0.05 compared to H3.3K27 WT group,
independent-sample t test, two-tailed. un = unmodification, me1 =mono-methylation, me2 = di-methylation,
me3 = tri-methylation, ac = acetylation
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abundance (Fig. 4d, Supplementary material 7). In
contrast, H3.1K27me2K36me1, H3.1K27me3K36me1,
H3.3K27me1K36me2/3 and H3.3K27me2K36me1 pep-
tide abundance negatively correlated with H3.3K27M
abundance (Supplementary material 7). On multivariate
analysis, K36me2/3 were the most common modifica-
tion states on the mutant H3.3K27MK36 peptide (F =
18,444.8, p < 0.01). As such, H3.3K27MK36me2 and
H3.3K27MK36me3 peptide abundance also positively
correlated with H3.3K27M abundance (Fig. 4e, f, Sup-
plementary material 7). Importantly, di-methylation
was the predominant modification state of the K36 resi-
due on the H3.3K27MK36 peptide, while K36Ac was
least abundant (Fig. 4g).
Fig. 3 Predominant histone modification states in DIPG tumor tissue. a K27 mono-methylation and K36 di-methylation are predominant
modification states on H3.1 and H3.3 tails in DIPG tumor tissue (n = 9). * p < 0.05 compared to all the other modification states (Tukey HSD, Post
Hoc Tests, one way ANOVA). b H4K16ac is the predominant acetylated residue in DIPG tumor tissue (n = 9). * p < 0.05 compared to all the other
modification states (Tukey HSD, Post Hoc Tests, one way ANOVA). c,d H3.3K36me2 abundance positively correlates with H3.1K36me2, and
negatively correlates with H3.3K27me1 (Pearson Correlation = 0.87 and − 0.84, respectively, all p < 0.01. Pearson Correlation, two-tailed). e, f
H4K16ac abundance positively correlates with H3.3K36me2, and negatively correlates with H3.3K27me1 (Pearson Correlation = 0.82 and − 0.94,
respectively, all p < 0.01. Pearson Correlation, two-tailed)
Table 2 Comparison of DIPG Tumor tissue and cell line
epiproteomic profiles. Differential fold change (FC) in
abundance (> 2 or < 0.5) between DIPG tumor tissue and cell




Mean Fold_Change p value
Tissue Cells Tissue/Cells
H3.3K36ac 2.4 15.8 0.2 < 0.01
H3K79me2 18.0 8.3 2.2 < 0.05
H3.3K36me1 12.7 5.3 2.4 < 0.05
H3K9ac 5.6 2.0 2.8 < 0.01
H4K20me3 8.5 2.2 3.9 < 0.01
H1.4K25me1 29.7 5.1 5.8 < 0.01
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Fig. 4 Distinct peptide modification states detected in DIPG tumor tissue. a Distinct combinations of modification states are observed on ten peptides in
H3.3K27M mutant tumor tissue (n= 9) relative to H3.3K27 wild-type (WT) tissue (n = 3).* p<0.05 compared to H3.3K27 WT group, Independent-sample t test, two-
tailed. b-f Scatter plots showing the correlation between relative abundance of H3.1K27me1K36me2/me3, H4K5un K8acK12unK16ac, and H3.3K27MK36me2/3
peptides with the H3.3K27M peptide in DIPG tumor tissue (Pearson Correlation=0.72, −0.79, 0.95, 0.99, and 0.97, respectively, all p<0.01. Pearson Correlation, two-
tailed, n= 12). g Relative abundance of H3.3K27MK36 peptide modification states in DIPG tumor tissue reveals K36me2 as the most abundant co-occurring
peptide with H3.3K27M mutation peptide. * p<0.05 compared to all the other groups (Tukey HSD, Post Hoc Tests, one way ANOVA, n= 9)
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Radiation treatment alters DIPG histone codes in vitro
As radiation treatment (RT) is the standard therapy for
DIPG, we examined the effects of RT on the glioma his-
tone code in vitro. We treated H3.3K27M mutant DIPG
cells (SF8628, DIPG007), H3.3K27 WT glioma cells
(U87) and normal astrocytes (NHA) with 9 Gy radiation,
and performed targeted histone mass spectrometry at 24
and 48 h post-treatment. Cell histone codes clustered
first by origin, then by treatment condition (Fig. 5a).
Comparative analysis revealed distinct differences in
relative peptide abundance after RT, most notably in
acetylated peptides (Supplementary material 8). In
DIPG007 cells, the relative abundance of H2AK5ac de-
creased with RT at 48 h (Fig. 5b). In contrast, H2AK5ac
abundance increased in NHA at 24 and 48 h, with no
significant change in SF8628 or U87 (Fig. 5b). At 24 and
48 h post-RT, all lines except DIPG007 showed a signifi-
cant increase in H4K16ac (Fig. 5c, Supplementary mater-
ial 7). H3K9me3 also significantly increased in NHA,
U87, and DIPG007, and trended towards a significant
increase in SF8628, after RT (Fig. 5d, Supplementary
material 8).
To determine the potential biological impact of ob-
served differences in histone modifications after RT
Fig. 5 Radiation treatment alters relative histone peptide modification states in DIPG, in vitro. a Unsupervised hierarchical clustering of pediatric
glioma cell line histone tail modification profiles reveals clustering by cell line and treatment condition. b-d Relative abundance of H2AK5ac,
H4K16ac and H3K9me3 peptides are distinct after radiation treatment. * p < 0.05 compared to Baseline; # p < 0.05 compared to 24 h post-RT
treatment (Tukey HSD, Post Hoc Tests, one way ANOVA)
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relative to controls, we compared cell gene expression
profiles in these same treatment groups. On functional
pathways analysis of genes identified as statistically signifi-
cantly differentially expressed by RT treated cells relative
to controls (fold change in expression > 2 or < − 2, ad-
justed p-value < 0.05), we identified DNA double-strand
break repair as a top canonical pathway activated in RT
treated DIPG cell lines (p-value 1.10 × 10− 21, Supplemen-
tary material 9). The top implicated molecular and cellular
function in RT treated cells, as well as the top network of
molecular interaction, was DNA replication, recombin-
ation and repair (p-value 2.06 × 10− 6),
Bromodomain inhibition alters DIPG histone codes
in vitro
We previously reported pre-clinical efficacy of JQ1, a
BET/Bromodomain inhibitor (BRDi), in DIPG [7]. We
observed that BRD proteins are enriched at acetylated
residues on histone H3 in DIPG cells and animal
models, and that JQ1 treatment results in decreased glo-
bal H3K27ac, with restoration of global H3K27 methyla-
tion [7]. To further elucidate the epigenetic effects of
JQ1 in DIPG, we examined its effects on histone codes
in SF8628, DIPG007, NHA, and U87 cells. As observed
with RT, PTM profiles clustered by cell line, then treat-
ment condition (Supplementary material 10). When ana-
lyzed individually, cell profiles cluster by treatment
condition (Fig. 6a, Supplementary material 11). In
DIPG007 cells, H3.3K27me1 decreased by 1.5% at 48 h
after JQ1 treatment compared to vehicle control, repre-
senting the only significant change in modification state
observed at that time point (Supplementary material 11).
A small increase in H3.3K27M abundance was also de-
tected in DIPG007 at 48 h (31.4% vs 26.9%, p = 0.067,
Supplementary material 11). Surprisingly, in DIPG007,
H3.3K27ac abundance was not significantly different
from control at 48 h post-treatment, though a marginal
decrease was observed at 24 h (1.65 and 1.95%, respect-
ively, p = 0.065, Supplementary material 11). These re-
sults were validated in DIPG007 and SF8628 cells via
western blot for H3K27M and H3K27ac (Supplementary
material 12).
In contrast, we observed statistically significant differ-
ences in abundance of multiple PTMs in SF8628 cells in
response to JQ1 (Supplementary material 11). Increased
H3.1K27me1 and decreased H3.3K36ac were seen at
both 24 h and 48 h (Fig. 6b, Table 3, Supplementary ma-
terial 11). Additional changes in relative modification
states were observed after either 24 or 48 h post-
treatment. For example, increased abundance of H3.1/
H3.3K27me2, H3.3K36me1, and H4K20me2 were seen
24 h (Fig. 6b-e, Table 3) and H3K79me2 at 48 h (Fig. 6f,
Table 3, Supplementary material 11). In addition, acetyl-
ation of H3K18 significantly decreased at 24 h (Fig. 6g,
Table 3, Supplementary material 11). Surprisingly, we
also observed a significant increase in H3.3K27M pep-
tides at 24 and 48 h after JQ1 treatment in SF8628 cells
(Fig. 6b, Table 3, Supplementary material 11).
Changes in histone PTM profiles were also observed in
H3.3K27 WT cell lines after exposure to JQ1. The relative
abundance of multiple PTMs were observed in U87 cells, in-
cluding H3.1K27me2/me3, H3.1K36me1/me3, H3.3K36me1/
ac, H3K14ac, H3K79me1, H3K4me1, and H4K5ac (Table 4,
Supplementary material 11). Lastly, distinct changes
were observed in NHAs after JQ1 treatment, including
methylation of H3.1K27, H3.1/3.3 K36, and H3K79me1,
and acetylation of H2AK5, H3.3K36, H3K18, and
H4K16ac (Table 5, Supplementary material 11).
To determine the potential biological impact of ob-
served differences in histone modifications after BRD in-
hibition relative to controls, we also compared cell gene
expression profiles in these treatment groups. On func-
tional pathways analysis of genes identified as statisti-
cally significantly differentially expressed by JQ1 treated
cells relative to controls (fold change in expression > 2
or < − 2, adjusted p-value < 0.05), we identified nucleo-
tide excision repair as the top canonical pathway acti-
vated in JQ1 treated DIPG cell lines (p-value 2.51 ×
10− 48, Supplementary material 9). Other canonical path-
ways implicated by JQ1 treated cell gene expression
profiles included DNA mismatch repair via non-
homologous end joining (NEMJ, p-value 2.53 × 10− 32),
while G2/M DNA damage check point regulation was
the top toxicology list match (p-value 2.68 × 10− 6). Top
upstream regulator effect networks implicated ANXA7
activation (resulting in DNA binding and conformational
modification, score 9.615), and TP73 inhibition (result-
ing in apoptosis, score − 15.254) in JQ1 treated DIPG
cells relative to controls.
Discussion
DIPG is an incurable pediatric brain tumor, with a high
rate of somatic missense mutations in genes encoding
histone H3.1 and H3.3 proteins. Here, we present com-
prehensive characterization of histone N-terminal tail
modification states in pediatric glioma specimens, in-
cluding H3.3K27M mutant DIPG tissue, using novel,
high-throughput proteomic analysis, revealing the effects
of radiotherapy and BRDi on the tumor epigenetic land-
scape. The greatest differences in PTMs between
H3K27M mutant and WT specimens were observed at
H3K27, H3K36, and H4K16ac, while H3K36me2 was the
highest co-occurring modification on the H3.3K27M
peptide, and H4K16 was the most acetylated residue.
These results suggest that H3K36me2 and H4K16ac may
serve as epigenetic signatures in DIPG, and that target-
ing these modification states may represent a potential
therapeutic strategy.
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Multiple groups have identified distinct DIPG molecu-
lar subtypes, with H3.3K27M mutant tumors associated
with shorter survival [22–30]. We found that H3.3K27M
significantly affects the histone PTM landscape, with cell
and tissue profiles clustering by mutation status. Further,
a decrease in global H3K27me2/3 has been observed in
H3.3K27M tumors, and our results corroborate these
data, [5, 7, 8, 10, 12, 13, 31]. Of note, a new subgroup of
DIPG lacking H3K27M mutation but still exhibiting
genomic H3K27me3 loss was recently reported [32]: we
did not observe this phenomenon in our cohort (Supple-
mentary material 4). Our H3K27M mutant specimens
Fig. 6 Bromodomain inhibition with JQ1 alters relative histone peptide modification states in DIPG, in vitro. a Unsupervised hierarchical clustering
of DIPG cell line SF8628 histone tail modification profiles reveals clustering by treatment condition. b-e Relative abundance of H3.1/3.3 K27,
H3.3K36, and H4K20 peptide modification states in SF8628 cells are distinct after JQ1 treatment. f-g Relative abundance of H3K79me2 and
H3K18ac peptides in SF8628 cell lines are distinct after JQ1 treatment. * p < 0.05 compared to DMSO group (independent-sample t test, two-tailed)
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also exhibit distinct modification states at H3K36 and
H4K16. Previous work showed that PRC2 loss coincides
with increased H3K36me2, and that an increase in
H3K36 methylation impacts methylation at H3K27 [33–
35]. Our results also confirm an increase in H3K36me2
in DIPG specimens on the H3.3K27M mutant peptide,
as previously detected via mass spectrometry of
H3.3K27M transgenic PDGF-driven murine glioblast-
oma [13]. Further, we detected high H4K16ac abun-
dance in DIPG cells and tissue specimens. A recently
published report characterizing high-throughput screen-
ing with nucleosome substrate methods demonstrates
small-molecule inhibitors of the human histone lysine
methyltransferase NSD2 [36], the writer of mono- and
di-methylation of H3K36 [37]; another report identified
DC_M01_7 as a novel inhibitor of MOF, the H4K16ac-
specific acetyltransferase [38, 39]. Therefore, H3K36me2
and H4K16ac may represent potential therapeutic tar-
gets in DIPG, and further investigation of this strategy is
warranted.
Using our method, we also characterized H3K27 and K36
modification states in cis, confirming me2/3 as the predom-
inant modifications, and acetylation as the least abundant,
on the H3.3K27MK36 peptide. We observed positive correl-
ation between H3.3K27M and H3.1K27K36me2, and nega-
tive correlation between H3.3K27M and H3.1K27K36me3.
Taken together, these results confirm that H3.3K27M affects
PTMs on both mutant and WT H3.1 and H3.3N-terminal
tails. Importantly, our study is the first, to our best know-
ledge, to quantify the relative amount of mutant H3.3K27M
peptide in DIPG tumor specimens. It is reported that rela-
tive abundance of mutant epidermal growth factor receptor
(EGFR) can predict benefit from EGFR-tyrosine kinase in-
hibitors for advanced non-small-cell lung cancer [40]. Longi-
tudinal quantification of the H3.3K27M peptide in patient-
derived specimens might similarly serve as a predictive bio-
marker for targeted therapy, and hence is worthy of consid-
eration when designing future clinical trials.
Radiation therapy (RT) is standard treatment for
DIPG, providing transient symptom relief but no change
Table 3 Effects of bromodomain inhibition with JQ1 on relative histone peptide abundance in SF8628 cells
Histone
code
Mean Fold (JQ1/DMSO) p_SF8628
Baseline DMSO 24 h DMSO 48 h JQ1 24 h JQ1 48 h 24 h 48 h 24 h 48 h
H3.1K27me1 31.4 31.1 28.7 32.8 33.5 1.1 1.2 < 0.05 < 0.05
H3.1K27me2 19.6 19.0 19.3 22.4 21.7 1.2 1.1 < 0.01 0.21
H3.3K27me2 6.9 6.7 7.7 7.8 9.8 1.2 1.3 < 0.01 0.33
H3.3K27M 21.0 21.5 19.0 24.4 26.0 1.1 1.4 < 0.05 < 0.05
H3.3K36me1 5.4 6.4 6.5 7.5 8.3 1.2 1.3 < 0.05 0.07
H3.3K36ac 12.0 13.5 16.0 9.7 7.9 0.7 0.5 < 0.05 < 0.01
H3K18ac 9.7 6.4 7.7 4.8 5.7 0.8 0.7 < 0.05 0.05
H3K79me2 11.0 12.7 11.2 12.3 14.4 1.0 1.3 0.86 < 0.05
H4K20me1 1.7 2.9 1.7 1.9 2.0 0.7 1.2 < 0.05 0.29
H4K20me2 91.7 89.2 87.1 94.8 89.2 1.1 1.0 < 0.01 0.38
Table 4 Effects of bromodomain inhibition with JQ1 on relative histone peptide abundance in U87 cells
Histone
code
Mean Fold (JQ1/DMSO) p_U87
Baseline DMSO 24 h DMSO 48 h JQ1 24 h JQ1 48 h 24 h 48 h 24 h 48 h
H3.1K27me2 34.7 34.2 35.2 37.0 38.6 1.1 1.1 < 0.05 < 0.05
H3.1K27me3 10.0 11.0 12.2 13.1 14.4 1.2 1.2 < 0.05 < 0.05
H3.1K36me1 19.9 19.6 18.3 17.9 19.0 0.9 1.0 < 0.05 0.39
H3.1K36me3 15.4 16.4 15.3 14.9 14.1 0.9 0.9 < 0.05 < 0.05
H3.3K36me1 10.7 11.1 10.4 11.4 12.5 1.0 1.2 0.51 < 0.05
H3.3K36ac 13.3 11.9 14.1 10.9 9.6 0.9 0.7 0.30 < 0.01
H3K14ac 45.0 37.3 28.5 30.2 26.8 0.8 0.9 < 0.05 0.38
H3K79me1 24.8 27.7 26.6 23.9 23.7 0.9 0.9 < 0.01 0.14
H3K4me1 21.1 17.6 16.7 12.8 15.5 0.7 0.9 < 0.01 0.69
H4K5ac 4.9 5.6 5.4 4.6 4.6 0.8 0.8 < 0.01 < 0.05
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in disease outcome [41]. Unfortunately, the mechanism of
radiation resistance is unknown, and radio-sensitizers pro-
vide no benefit [42]. Patients with the H3.3K27M muta-
tion also respond more poorly to RT [24]. Our study
reveals RT can induce cell-specific and peptide-specific
changes in histone acetylation, underscoring the hetero-
geneity of DIPG and warranting consideration when using
histone deacetylase / acetyltransferase inhibitors in com-
bination with RT. Importantly, H3K9me3 abundance in-
creased in all four cell lines after RT, which kills rapidly
proliferating cancer cells by inducing DNA damage be-
yond cellular capacity for repair, including DNA double-
strand breaks (DSBs) [43–45]. DSB repair is linked to
rapid changes in epigenetic modifications, including in-
creased H3K9 methylation, to recruit DNA repair pro-
teins. Importantly, H3K9 methyltransferase G9a inhibition
(BIX-01294) increases radio-sensitivity in glioma [46]. In-
deed, on functional pathways analysis of cell gene expres-
sion profiles, we found DSB repair pathways implicated in
RT treated cell lines relative to controls. These data sug-
gest that combination therapy RT with G9a inhibition,
aimed at reducing H3K9me3 levels and hence DNA DSB
repair, may also be a useful therapeutic strategy in DIPG.
We found distinct DIPG histone codes after treatment
with JQ1, a BET/ bromodomain inhibitor. BET domain
proteins are epigenetic readers that bind acetylated his-
tones via their bromodomain region to regulate gene
transcription [46–48]. BET inhibitors dislodge acetylated
histone readers from chromatin, leading to oncogene re-
pression [49–51]. JQ1 is the best known BET inhibitor,
and induces a dose-dependent reduction in DIPG cell
viability and genomic H3K27ac in vitro and in vivo [7, 52,
53]. Our results showed increased mono- and/or di-
methylation of multiple residues with JQ1 treatment, con-
sistent with previous reports that JQ1 globally reduces
acetylation and increases methylation [7]. Since mono-
methylation of H3K27, H3K79, and H4K20 are all linked to
gene activation, whereas tri-methylation of H3K27 and
H3K79 are linked to repression [54], these findings may
provide additional insight into the mechanism by which
BRDi alters tumorigenic gene expression in DIPG.
H4K20me, which is functional in DNA repair, represents a
binding site for the 53BP1 protein; H3K9me3 and
H4K20me3 represent epigenetic markers important to the
function of 53BP1 in non-homologous end joining (NHEJ)
repair [55]. In line with these known functions, pathways
analysis of differential gene expression profiles implicated
nucleotide excision repair and DNA mismatch repair via
NHEJ as top activated pathways in JQ1 treated cells, com-
pared to controls. As such, additional studies of the mechan-
ism by which JQ1 may augment response to RT are
necessary. Lastly, we also observed that reduction of histone
acetylation in DIPG was greatest at 24 h, which may be im-
portant to consider when determining JQ1 dosing regimens.
Because fresh DIPG tissue is very rare, we chose to
analyze archival post-mortem tissue specimens for this
study, raising the possibility of treatment-induced effects.
However, the patterns of peptide abundance observed in
tumor tissues were similar to treatment-naïve cell lines.
Analysis of treatment fresh tumor tissue specimens with
this approach will be crucial to teasing out tumor biology
from the effects of therapy. Optimization of our technical
approach to minimize the amount of starting tumor tissue
necessary for this purpose is currently underway.
Conclusions
In summary, targeted histone tail mass spectrometry of
high grade glioma cell lines and tissues, including rare
DIPG tumor tissue specimens, reveals distinct peptide
modification states by H3.3K27M mutation status. Our
study is the first to quantify the H3.3K27M peptide in
DIPG, representing an exciting new opportunity to apply
this technique on clinical specimens at diagnosis, and
potentially throughout the course of treatment to guide
clinical management. We also distinct epigenetic signa-
tures of DIPG, including H3K36me2 and H4K16ac,
which may represent novel therapeutic vulnerabilities for
more effective treatment of this devastating disease.
Table 5 Effects of bromodomain inhibition with JQ1 on relative histone peptide abundance in NHA cells
Histone
code
Mean Fold (JQ1/DMSO) p_NHA
Baseline DMSO 24 h DMSO 48 h JQ1 24 h JQ1 48 h 24 h 48 h 24 h 48 h
H2AK5ac 8.8 6.4 6.2 3.9 4.7 0.6 0.8 0.06 < 0.05
H3.1K27me3 19.7 18.3 18.2 22.0 24.0 1.2 1.3 < 0.05 < 0.05
H3.1K36me1 14.6 14.5 13.9 16.4 15.9 1.1 1.1 0.21 < 0.05
H3.1K36me2 27.6 29.2 29.7 25.6 24.1 0.9 0.8 0.08 < 0.05
H3.3K36me1 8.7 9.2 8.5 10.6 11.0 1.2 1.3 0.17 < 0.01
H3.3K36ac 8.5 8.8 10.0 6.3 7.1 0.7 0.7 < 0.05 < 0.01
H3K18ac 10.1 8.1 7.3 6.2 6.0 0.8 0.8 0.10 < 0.05
H3K79me1 14.3 15.2 16.1 17.5 14.2 1.2 0.9 0.27 < 0.01
H4K16ac 28.5 27.5 27.3 26.2 30.8 1.0 1.1 0.66 < 0.01
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